KR20130089559A - Anti-aging composition - Google Patents
Anti-aging composition Download PDFInfo
- Publication number
- KR20130089559A KR20130089559A KR1020120011003A KR20120011003A KR20130089559A KR 20130089559 A KR20130089559 A KR 20130089559A KR 1020120011003 A KR1020120011003 A KR 1020120011003A KR 20120011003 A KR20120011003 A KR 20120011003A KR 20130089559 A KR20130089559 A KR 20130089559A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- tangeretin
- effect
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000003712 anti-aging effect Effects 0.000 title description 4
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000002087 whitening effect Effects 0.000 claims abstract description 16
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 7
- 230000003779 hair growth Effects 0.000 claims abstract description 5
- 241000675108 Citrus tangerina Species 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 7
- 230000003658 preventing hair loss Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 201000004384 Alopecia Diseases 0.000 abstract description 7
- 230000000638 stimulation Effects 0.000 abstract description 3
- 231100000360 alopecia Toxicity 0.000 abstract 2
- 230000003405 preventing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- -1 pack Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 102000029816 Collagenase Human genes 0.000 description 10
- 108060005980 Collagenase Proteins 0.000 description 10
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229960002424 collagenase Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 229960004337 hydroquinone Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- WAYBOGPIIWWHLR-UHFFFAOYSA-N C(C(C(C)O)O)O.C(CC(C)O)O Chemical compound C(C(C(C)O)O)O.C(CC(C)O)O WAYBOGPIIWWHLR-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- QRNKPPAMVATJRK-UHFFFAOYSA-N CCO.CC(O)CO.OCCN(CCO)CCO Chemical compound CCO.CC(O)CO.OCCN(CCO)CCO QRNKPPAMVATJRK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- PBWHIVNNEMWUKP-UHFFFAOYSA-N [Na].CC(O)CO.OCC(O)CO Chemical compound [Na].CC(O)CO.OCC(O)CO PBWHIVNNEMWUKP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- BMSYINVLSXEZEN-UHFFFAOYSA-M sodium;benzoic acid;dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O.OC(=O)C1=CC=CC=C1 BMSYINVLSXEZEN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 탄게레틴(tangeretin)을 유효성분으로 포함하는 항노화 활성을 가지는 조성물에 관한 것이다.The present invention relates to a composition having anti-aging activity comprising tangeretin (tangeretin) as an active ingredient.
피부는 인체에서 가장 큰 조직이며 일차 방어막으로서 외부의 자극으로부터 피부 내부를 보호해주는 중요한 역할을 한다. 이러한 피부는 사람에 따라 또는 나이가 들어감에 따라 색이 상이하게 나타나는데, 이는 피부 내부의 멜라닌(melanin)농도와 분포에 따라 결정되어진다. 피부흑화(melanogenesis)는 멜라닌 색소생성세포(melanocyte)에서 자외선 등의 자극에 대한 방어기작으로 멜라닌 생성활동이 증가되고 이로 말미암아 만들어진 다량의 멜라닌이 각질형성세포(keratinocyte)로 전이되어 피부표피층에 축척된 결과이다. 비록 멜라닌이 피부보호작용을 하나 피부의 과색소침착은 기미, 주근깨, 피부염증 후의 피부흑화, 노인성 색소반점 등을 일으키며 이로 인해 당사자에게 미용상의 불편뿐만 아니라 정신적으로 부정적인 영향을 미쳐 사회활동에 불편을 초래하기도 한다. 멜라닌 생성 과정은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하여 도파(DOPA), 도파퀴논(dopaquinone)으로 바뀐 후 비효소적인 산화 반응을 거쳐 만들어 지며, 이것이 피부 내에 이상침착하여 기미, 검버섯 등이 생기는 것이라고 알려져 있다. Skin is the largest tissue in the human body and plays an important role in protecting the interior of the skin from external stimuli as a primary barrier. These skins appear differently in color with age or with age, depending on the concentration and distribution of melanin inside the skin. Skin melanogenesis is a defense mechanism against stimuli such as ultraviolet light in melanocyte-producing cells (melanocyte), and a large amount of melanin produced by the melanin is transferred to keratinocyte and accumulated on the skin surface layer Results. Although melanin protects the skin, hyperpigmentation of the skin causes skin irritation, freckles, darkening of the skin after inflammation of the skin and aging pigmentation spots. This causes the discomfort of the person not only the cosmetic discomfort but also the psychological negative affect on the social activities. . Melanin is produced by tyrosine tyrosine, an enzyme called tyrosinase, converted into DOPA or dopaquinone, and then enzymatically oxidized to form an abnormal deposit in the skin And it is known that it produces spots and black spots.
한편, 사람의 피부는 외부의 화학적, 물리적 자극으로 인해 피부의 정상기능이 저하되고 문제가 생겨 피부의 노화현상이 촉진되어 피부 손상이 유발된다. 그러한 피부의 노화 중의 하나로서 피부주름이 있는데, 일반적으로 피부 주름은 피부의 수분 함유량, 콜라겐 함유량 및 외부 환경에 대한 면역 작용 능력 등 여러 가지 요인들의 복합적인 작용에 의해 생성되는 것으로 알려져 있다. 이러한 요인들 중 주름의 형성에 가장 큰 영향을 미치는 것은 콜라겐의 생성량과 콜라겐의 함량을 감소시키는 콜라겐 분해 효소인 콜라게네이즈의 발현량과 활성이다.On the other hand, the skin of a person is deteriorated due to external chemical and physical stimulation, the skin's normal function is degraded, the aging phenomenon of the skin is promoted, causing skin damage. One of such aging of the skin is skin wrinkles. In general, skin wrinkles are known to be produced by a complex action of various factors such as the moisture content of the skin, collagen content and the ability to act on the external environment. Among these factors, the most influential effect on the formation of wrinkles is the expression and activity of collagenase, a collagen degrading enzyme that reduces collagen production and collagen content.
자동차 매연, 환경오염 등으로 인하여 호르몬 불균형 현상이 심화되고 있다. 이로 인해 탈모 발생율이 높아지고, 발생연령도 낮아지고 있으며, 피부면역시스템의 부조화가 초래되어 다양한 피부질환 등이 발생하고 있다. Hormonal imbalances are intensifying due to automobile smoke and environmental pollution. As a result, the incidence of hair loss increases, the age of incidence decreases, and incompatibility of the skin immune system is caused, resulting in various skin diseases.
따라서, 미적인 차원 뿐만 아니라 심각한 사회문제로 대두되고 있는 여러 가지 현상 즉, 기미, 주름, 탈모 등과 같은 현상을 효과적으로 해결할 수 있는 물질 개발이 심도 깊게 연구되고 있다.Therefore, the development of materials that can effectively solve various phenomena, such as blemishes, wrinkles, and hair loss, which are emerging as serious social problems as well as the aesthetic dimension, are being studied in depth.
상기한 바와 같은 피부의 미백 및 주름 형성을 억제하기 위하여 다양한 조성물들이 종래부터 사용되어 왔다. 예를 들면 L-아스코르브산(L-ascorbic acid) 및 이의 유도체, 하이드로퀴논(hydroquinone), 알부틴 및 감초, 상백피 등에서 추출한 다양한 추출물들이 피부 미백제 및 주름개선제 등으로 이용되고 있다. 그러나 L-아스코르브산은 쉽게 산화되어 피부에 자극을 유발하며, 이를 배합한 화장료는 변색, 변취되는 문제를 야기하고, 식물추출물 유래의 물질들은 식물의 산지에 따라 효능의 차이가 심하여 제품의 균질성이 유지되기 어렵고, 알부틴은 효과가 낮은 단점이 있다.
Various compositions have conventionally been used to inhibit whitening and wrinkle formation of the skin as described above. For example, various extracts extracted from L-ascorbic acid and derivatives thereof, hydroquinone, arbutin and licorice, and lettuce skin are used as skin whitening agents and anti-wrinkle agents. However, L-ascorbic acid is easily oxidized to cause irritation to the skin, and the cosmetics containing it cause discoloration and discoloration problems. The substances derived from plant extracts have a great difference in efficacy depending on the plant's origin, thus maintaining homogeneity of the product. It is difficult to do, and arbutin has the disadvantage of low effect.
상기한 목적을 위하여 본 발명은 피부 미백효과, 주름개선 효과 및 탈모 방지 효과가 우수하고 인체에 안전한 탄게레틴(tangeretin)을 유효성분으로 포함하는 항노화 조성물을 제공한다.
For the above purpose, the present invention provides an anti-aging composition comprising tangertin as an active ingredient, which is excellent in skin whitening effect, wrinkle improvement effect, and hair loss prevention effect, and is safe for human body.
상기한 바와 같은 본 발명의 기술적 과제는 다음과 같은 수단에 의해 달성되어진다.
The technical problem of the present invention as described above is achieved by the following means.
(1) 멜라닌 생성 억제, 주름개선 효과 및 탈모 방지 효과가 뛰어난 하기 화학식 1의 탄게레틴을 유효성분으로 포함하는 항노화 조성물을 제공한다. (1) Provides an anti-aging composition comprising tangeretine of the general formula (1) excellent in melanin production inhibition, wrinkle improvement and hair loss prevention effect.
[화학식 1][Formula 1]
본 발명의 탄게레틴(tangeretin)을 유효성분으로 포함하는 피부외용제 조성물은 우수한 미백 효과, 주름개선 효과 및 탈모 방지 효과를 가지고 있으며, 인체에 대한 피부 자극도 거의 없어 제품의 안전성이 우수하므로, 피부 미백용 화장료 조성물 및/또는 주름개선용 화장료 조성물로 유용하게 사용할 수 있다.
The external preparation composition for skin containing tangeretine of the present invention as an active ingredient has an excellent whitening effect, an anti-wrinkle effect, and an anti-hair loss effect, and almost no skin irritation to the human body, so the safety of the product is excellent, thus whitening the skin. It can be usefully used as a cosmetic composition for cosmetics and / or a cosmetic composition for wrinkle improvement.
이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
탄게레틴은 다양한 감귤류 식물에서 가장 흔하게 발견되며, 특히 탄제린(tangerine)과 오렌지(orange)의 껍질에서 발견되며, 과즙에도 이 물질이 존재하지만, 특히 껍질에 매우 많은 양이 존재한다. 탄게레틴은 콜레스테롤 분해, 항암, 신경보호 효과 및 항균 효과가 보고된 바 있으나 본 발명과 명백한 차이가 있다. Tangeretine is most commonly found in a variety of citrus plants, especially in the tangerine and orange peels, which are also present in juices, but especially in the skin. Tangeretine has been reported to lower cholesterol, anticancer, neuroprotective and antimicrobial effects, but there is a clear difference from the present invention.
본 발명에서 사용되는 탄게레틴은 해당 분야에 잘 알려진 방법에 의하여 다양한 감귤류(citrus sp.) 식물에 함유되어 있으며, 이것에 한정되지는 않는다. 예를 들어, 본 발명에서는 탄게레틴을 중국(Santa Cruz Biotechnology, Inc.)에서 구입하여 사용하였으며, 질량 분석 스펙트럼으로 상기 화합물이 탄게레틴임을 확인하였다. 상기 정제물의 분자량은 질량 분석 스펙트럼(Mass spectrum)에서 373의 [분자량 + H]+ 피크로부터 분자량이 372.4(C20H20O7)임을 확인하였다. Tangeretine used in the present invention is contained in various citrus sp. Plants by methods well known in the art, but is not limited thereto. For example, in the present invention, tangeretine was purchased from China (Santa Cruz Biotechnology, Inc.) and used, and mass spectrometry confirmed that the compound was tangeretine. The molecular weight of the purified product was confirmed to have a molecular weight of 372.4 (C 20 H 20 O 7 ) from the [molecular weight + H] + peak of 373 in the mass spectrum.
본 발명의 탄게레틴은 멜라닌 생성을 억제함으로써 미백 효과가 우수하며, 콜라게네이즈 활성 억제 및 콜라겐 합성 촉진을 통하여 주름 개선 효과가 우수하며, 탈모 방지 효과도 우수하다. 따라서 상기 탄게레틴은 피부 미백, 주름개선 및 탈모 방지용 피부외용제 조성물로서 유용하다. 또한, 본 발명의 조성물은 피부누적 자극 시험에서 뚜렷한 양상을 나타내지 않아 인체 피부에 안전하다.Tangeretine of the present invention is excellent in whitening effect by inhibiting the production of melanin, excellent wrinkle improvement effect by inhibiting collagenase activity and promoting collagen synthesis, and also excellent in hair loss prevention effect. Therefore, the tangeretine is useful as an external skin composition for skin whitening, wrinkle improvement and hair loss prevention. In addition, the composition of the present invention does not show a clear appearance in the cumulative stimulation test of the skin and is safe for human skin.
상기 탄게레틴을 포함하는 피부 외용 연고 또는 화장료 제조시에 함유되는 탄게레틴의 함량은 조성물 총량에 대하여 건조 중량으로 0.00001 내지 10.0 중량%, 바람직하게는 0.001 내지 1.0 중량%이다. 탄게레틴의 함량이 조성물 총량에 대하여 건조 중량으로 0.00001 중량% 미만이면 피부 미백 등의 뚜렷한 효과를 기대할 수 없었고, 10.0 중량%를 초과하면 함유량의 증가에 따라 뚜렷한 효과의 증가가 나타나지 않았다.The content of tangeretine contained in the preparation of the skin external ointment or the cosmetic including the tangeretine is 0.00001 to 10.0% by weight, preferably 0.001 to 1.0% by weight, based on the total weight of the composition. If the content of the tangeretine is less than 0.00001% by weight in dry weight with respect to the total amount of the composition, no obvious effect such as skin whitening could be expected.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서의 탄게레틴 이외에 피부외용제 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The components included in the cosmetic composition of the present invention include components conventionally used in the external preparation composition for skin, in addition to tangeretine as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 수렴 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, astringent lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
이하 본 발명의 내용을 실시예 내지 실험예를 참조하여 보다 상세하게 설명하고자 한다. 다만 하기 예시된 실시예 등은 본 발명의 이해를 돕기 위해 제시되는 것일 뿐 이에 의해 본 발명의 권리범위가 한정되는 것으로 해석되어서는 아니된다.
Hereinafter, the content of the present invention will be described in more detail with reference to Examples to Experimental Examples. However, the following examples and the like are presented to aid the understanding of the present invention and should not be construed as limiting the scope of the present invention.
[실험예 1] 탄게레틴의 세포 수준에서의 멜라닌 생성 저해 효과 시험Experimental Example 1 Experiment of Melanin Inhibition Effect at the Cell Level of Tangeretetin
탄게레틴(tangeretin)을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 미백 효과를 다음과 같이 실험하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980).Tangerine was added to the culture medium of B-16 mouse melanoma cells to test the whitening effect at the cellular level (Lotan R., Lotan D. Cancer Res. 40: 3345). -3350, 1980).
탄게레틴을 최종 농도가 1 ㎍/ml, 5 ㎍/ml, 50 ㎍/m가 되도록 하여 B-16 멜라노마 세포의 배양시 배양액에 첨가하고, 3일간 배양한 후 세포들을 트립신(Trypsin)으로 처리하고, 배양 용기로부터 떼어내 원심 분리한 후, 멜라닌을 추출하였다. 추출된 멜라닌에 수산화 나트륨용액(1N 농도) 1 ml를 가하여 약 10 분 동안 끓여 멜라닌을 녹이고, 분광 광도계로 400 나노미터(nm)에서 흡광도를 측정하여 생성된 멜라닌의 양을 단위 세포 수당(106 cell)의 흡광도를 나타내는 방법으로 실험을 수행하였다. 이와 같은 실험을 3회 반복하고 그 평균값을 사용하여 대조군에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하고, 그 결과를 하기 표 1에 나타내었다.Tangeretine is added to the culture medium at the final concentration of 1 μg / ml, 5 μg / ml, 50 μg / m and cultured for B-16 melanoma cells, and cultured for 3 days and treated with trypsin. The melanin was extracted after removing from the culture vessel and centrifuging. Sodium hydroxide solution to the extraction of melanin (1N concentration) 1 ml and the reaction mixture was dissolved melanin boiled for about 10 minutes, the amount of the produced melanin by measuring the absorbance at 400 nanometers (nm) with a spectrophotometer unit cell allowance (10 6 The experiment was carried out by a method showing the absorbance of the cell). The experiment was repeated three times and the average value was used to calculate the relative melanin production relative to the control group as inhibition rate (%), and the results are shown in Table 1 below.
반복수 = 3 Iterations = 3
상기 표 1에서 보는 바와 같이, 탄게레틴은 종래에 알려진 미백 물질인 하이드로퀴논과 비교할 때 배양된 쥐의 멜라노마 세포에 대하여 대등한 멜라닌 생성 억제능이 있음을 알 수 있다. 또한 하이드로퀴논은 저농도에서 강력한 멜라닌 생성 억제능을 가지지만 세포 독성이 심해 10 ㎍/ml 이상에서는 실험을 할 수 없으나, 탄게레틴은 50 ㎍/ml농도에서도 세포 독성을 나타내지 않으면서도 하이드로퀴논보다 높은 멜라닌 생성 억제 효과를 갖고 있으므로 이는 본 발명이 기미나 주근깨 개선 및 피부 미백에 매우 유용하게 사용될 수 있다는 것을 나타냈다.
As shown in Table 1, it can be seen that tangeretin has a comparable melanin production inhibitory ability against cultured melanoma cells compared to hydroquinone, which is a known whitening substance. In addition, hydroquinone has strong melanin production inhibitory ability at low concentration but can not be tested at more than 10 ㎍ / ml due to severe cytotoxicity. Since it has an inhibitory effect, it has been shown that the present invention can be very usefully used for improving blemishes and freckles and skin whitening.
[실험예 2] 탄게레틴의 세포수준에서의 주름개선 효과 시험Experimental Example 2 Anti-wrinkle Effect Test of Tangeretine at Cell Level
주름개선효과는 통상 콜라겐 생합성능과 콜라게네이즈 분해 억제능 및 사람에 대한 임상시험으로서 효과를 측정할 수 있다.The anti-wrinkle effect can usually be measured as collagen biosynthesis and collagenase degradation inhibitory effect and clinical trial in humans.
사람의 정상 섬유아세포(human normal fibroblast)를 DMEM배지가 들어있는 6-웰 마이크로플레이트에 접종시키고(2×105세포/웰) 5%농도의 CO2 배양기에 37℃로 24시간 배양하였다. 24시간 후, 각 웰에서 배지를 제거하고 농도별로 시료를 처리한 다음 24시간 동안 다시 배양하였다. 24시간 후, 세포배지를 수집하여 샘플을 제조하였다. Human normal fibroblasts were inoculated into a 6-well microplate containing DMEM medium (2 x 10 5 cells / well) and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours. After 24 hours, the medium was removed from each well, samples were treated by concentration and then incubated again for 24 hours. After 24 hours, the cell culture medium was collected to prepare a sample.
콜라겐 합성량은 콜라겐 측정 키트(Procollagen type I C-peptide EIA kit(MK101), 다카라, 교토, 일본)를 이용하여 세포배지 내에서의 프로콜라겐(procollagen)타입 I C-펩타이드(type I C-peptide : PICP)의 양을 측정하고 분석하였다.The amount of collagen synthesis was measured by using a procollagen type I C-peptide (type I C-peptide) in a cell culture medium using a collagen measurement kit (Procollagen type I C-peptide EIA kit (MK101), Takara, : PICP) was measured and analyzed.
콜라겐을 분해하는 콜라게네이즈의 활성정도를 측정하는 방법으로 콜라게네이즈에 대한 항체를 이용하였다. 콜라게네이즈 활성은 타입 I 콜라게네이즈 어세이 키트(Amersham Biosciences, RPN2629)를 이용하였으며, ELISA 판독기로 흡광도를 측정하였다. 측정된 표준치는 평균 ±표준편차의 형태로 표시하였고 SPSS/PC+프로그램을 이용하여 t-test로 유의성을 검정하였고, 그 결과를 하기 표 2에 나타내었다.An antibody against collagenase was used as a method for measuring the activity of collagenase degrading collagen. The collagenase activity was measured using a Type I collagenase assay kit (Amersham Biosciences, RPN2629) and the absorbance was measured with an ELISA reader. The measured standard values were expressed in the form of mean ± standard deviation and tested for significance by t-test using the SPSS / PC + program. The results are shown in Table 2 below.
표 2에 나타난 바와 같이, 탄게레틴은 농도 의존적으로 콜라겐합성을 증가시켰으며, 또한 농도의존적으로 콜라게네이즈 활성을 억제하였다. 따라서 탄게레틴은 주름개선 효능을 가지고 있음을 알 수 있었다.
As shown in Table 2, tangeretine increased collagen synthesis in a concentration-dependent manner, and also inhibited collagenase activity in a concentration-dependent manner. Therefore, it can be seen that tangeretine has a wrinkle improvement effect.
[실험예 3] 탄게레틴의 탈모방지 및 육모효과 Experimental Example 3 Tangeretetin Hair Loss Prevention and Hair Growth Effect
탈모방지와 육모효과에 대한 효과를 측정하기 위하여 시료를 방부제와 점증제만 함유한 하이드로겔 베이스로 만들어 실시하였다. 제조한 발모촉진용 외용액제를 이용하여 탈모 환자 10명의 탈모부위에 1일 2회 각각 2cc씩 6개월간 적용하였다. 그 결과 탈모 환자 7명에게서 새로운 모근이 발생하는 등의 우수한 효과가 있는 것으로 나타났다. 시험결과는 다음과 같다. 대조군으로 미녹시딜제제를 사용하였다.In order to measure the effect on hair loss prevention and hair growth, a sample was made of a hydrogel base containing only preservatives and thickeners. Using the prepared hair-promoting external preparation, 10 cc of hair loss was applied to the bald area of 10 patients with hair loss twice a day for 6 months. As a result, it was found that there were excellent effects such as the development of new hair roots in 7 hair loss patients. The test results are as follows. Minoxidil formulation was used as a control.
표 3에 나타난 바와 같이, 본 발명의 탄게레틴은 발모제로 이용되는 미녹시딜과 유사한 발모 효과를 발휘한다는 것을 알 수 있다.
As shown in Table 3, it can be seen that the tangeretine of the present invention exhibits a hair growth effect similar to that of minoxidil used as a hair regrowth agent.
[실시예 1 및 비교예 1][Example 1 and Comparative Example 1]
하기 표 4에 나타낸 각각의 성분을 하기 표 4에 나타난 비율과 같이 혼합하여 피부 외용 연고를 제조하였다. Each component shown in Table 4 below was mixed in the ratio shown in Table 4 to prepare an external skin ointment.
디에틸 세바케이트
경납
폴리옥시에틸렌올레일에테르포스페이트
벤조산 나트륨
바셀린Tangerine
Diethyl sebacate
Prepayment
Polyoxyethylene oleyl ether phosphate
Sodium benzoate
vaseline
8
5
6
적량
잔량*0.01
8
5
6
Suitable amount
Remaining amount *
8
5
6
적량
잔량*-
8
5
6
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실시예 2 및 비교예 2] Example 2 and Comparative Example 2;
하기 표 5에 나타낸 각각의 성분을 하기 표 5에 나타난 비율과 같이 혼합하여 영양 크림을 제조하였다. Each ingredient shown in Table 5 below was mixed in the ratio shown in Table 5 to prepare a nourishing cream.
스테아린산
세탄올
피이지-20 소비탄 모노스테아레이트
소비탄 모노스테아레이트
미네랄 오일
트리옥타노에이트
트리에탄올아민
카보머
글리세린
프로필렌글리콜
방부제
향
정제수Tangerine
Stearic acid
Cetanol
Fiji-20 sorbitan monostearate
Sorbitan monostearate
Mineral oil
Trioctanoate
Triethanolamine
Carbomer
glycerin
Propylene glycol
antiseptic
incense
Purified water
1.0
2.0
1.0
1.0
10.0
5.0
0.5
0.2
5.0
3.0
적량
적량
잔량*0.01
1.0
2.0
1.0
1.0
10.0
5.0
0.5
0.2
5.0
3.0
Suitable amount
Suitable amount
Remaining amount *
1.0
2.0
1.0
1.0
10.0
5.0
0.5
0.2
5.0
3.0
적량
적량
잔량*-
1.0
2.0
1.0
1.0
10.0
5.0
0.5
0.2
5.0
3.0
Suitable amount
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실시예 3 및 비교예 3] Example 3 and Comparative Example 3;
하기 표 6에 나타낸 각각의 성분을 하기 표 6에 나타난 비율과 같이 혼합하여 유연 화장수를 제조하였다. Each component shown in Table 6 was mixed in the same ratio as shown in Table 6 to prepare a flexible lotion.
에탄올
폴리옥시에틸렌경화피마자유
파라옥시안식향산메칠
글리세린
1,3-부틸렌글리콜
향
색소
정제수Tangerine
ethanol
Polyoxyethylene hardened castor oil
Paraoxybenzoic Acid Methyl
glycerin
1,3-butylene glycol
incense
Pigment
Purified water
10.0
1.0
2
5.0
6.0
적량
적량
잔량*0.01
10.0
1.0
2
5.0
6.0
Suitable amount
Suitable amount
Remaining amount *
10.0
1.0
2
5.0
6.0
적량
적량
잔량*-
10.0
1.0
2
5.0
6.0
Suitable amount
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실시예 4 및 비교예 4][Example 4 and Comparative Example 4]
하기 표 7에 나타낸 각각의 성분을 하기 표 7에 나타난 비율과 같이 혼합하여 엣센스를 제조하였다. Each component shown in Table 7 was mixed in the same ratio as shown in Table 7 to prepare an essence.
프로필렌글리콜
글리세린
히아루론산나트륨수용액(1%)
에탄올
폴리옥시에틸렌경화피마자유
파라옥시안식향산메칠
카보머
트리에탄올아민
향
정제수Tangerine
Propylene glycol
glycerin
Sodium hyaluronate aqueous solution (1%)
ethanol
Polyoxyethylene hardened castor oil
Paraoxybenzoic Acid Methyl
Carbomer
Triethanolamine
incense
Purified water
10.0
10.0
5.0
5.0
1.0
0.1
0.3
0.4
적량
잔량*0.01
10.0
10.0
5.0
5.0
1.0
0.1
0.3
0.4
Suitable amount
Remaining amount *
10.0
10.0
15.0
5.0
1.0
0.1
0.3
0.4
적량
잔량*-
10.0
10.0
15.0
5.0
1.0
0.1
0.3
0.4
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실시예 5 및 비교예 5]Example 5 and Comparative Example 5
하기 표 8에 나타낸 각각의 성분을 하기 표 8에 나타난 비율과 같이 혼합하여 팩을 제조하였다. Each component shown in Table 8 below was mixed in the ratio shown in Table 8 to prepare a pack.
글리세린
프로필렌글리콜
폴리비닐알코올
에탄올
폴리옥시에틸렌경화피마자유
폴리옥시에틸렌올레일에칠
파라옥시안식향산메칠
향
색소
정제수Tangerine
glycerin
Propylene glycol
Polyvinyl alcohol
ethanol
Polyoxyethylene hardened castor oil
Polyoxyethylene Oleethyl
Paraoxybenzoic Acid Methyl
incense
Pigment
Purified water
5.0
4.0
15.0
8.0
1.0
1.0
0.2
적량
적량
잔량*0.01
5.0
4.0
15.0
8.0
1.0
1.0
0.2
Suitable amount
Suitable amount
Remaining amount *
5.0
4.0
15.0
8.0
1.0
1.0
0.2
적량
적량
잔량*-
5.0
4.0
15.0
8.0
1.0
1.0
0.2
Suitable amount
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실시예 6 및 비교예 6]Example 6 and Comparative Example 6
하기 표 9에 나타낸 각각의 성분을 하기 표 9에 나타난 비율과 같이 혼합하여 영양 화장수를 제조하였다. Each component shown in Table 9 was mixed in the same ratio as shown in Table 9 to prepare a nourishing lotion.
폴리옥시에틸렌경화피마자유
파라옥시안식향산메칠
글리세린
1,3-부틸렌글리콜
카보머
트리에탄올아민
프로필렌글리콜
에탄올
카르복시비닐폴리머
색소
향
정제수Tangerine
Polyoxyethylene hardened castor oil
Paraoxybenzoic Acid Methyl
glycerin
1,3-butylene glycol
Carbomer
Triethanolamine
Propylene glycol
ethanol
Carboxyvinyl polymer
Pigment
incense
Purified water
1.0
적량
6.0
5.0
0.2
0.3
5.0
2
1
적량
적량
잔량*0.01
1.0
Suitable amount
6.0
5.0
0.2
0.3
5.0
2
One
Suitable amount
Suitable amount
Remaining amount *
1.0
적량
6.0
5.0
0.2
0.3
5.0
3.2
0.1
적량
적량
잔량*-
1.0
Suitable amount
6.0
5.0
0.2
0.3
5.0
3.2
0.1
Suitable amount
Suitable amount
Remaining amount *
*: 전체가 100 중량%가 되도록 하는 양
*: Amount to be 100% by weight in total
[실험예 4] 탄게레틴의 임상에서의 미백 효과 시험 [Example 4] tange test when the whitening effect of the clinician retinoic
피시험자로 건강한 남녀 20명씩을 선정하여 양팔의 하박부에 직경 7 mm 크기의 구멍이 6 개씩 2 줄로 파인 알루미늄 호일을 덮은 후, 팔에서 10 cm 거리에서 일광 조사기(ORIEL Solar Simulator 1000W)로 60 mJ/㎠의 광량을 조사하였다. 조사하기 3일 전부터 조사 후 3주 째까지 1일 2회씩 실시예 1-6 및 비교예 1-6에 따라 제조된 탄게레틴을 함유한 시료와 탄게레틴이 함유되지 않은 기제를 한 쌍으로 같은 줄에 도포 하였다. 여기서 실시예 5 및 비교예 5의 팩 처방의 경우 도포한 다음 15분 후에 떼어내었다. 상기 각각에 대하여 실시예와 비교예의 색소 침착도를 육안으로 판정하였으며 그 결과는 하기 표 10에 나타내었다.Twenty healthy men and women were selected as test subjects, and the lower arm of each arm was covered with two rows of aluminum foil having 6 rows of 7 mm in diameter, and 60 mJ with a ORIEL Solar Simulator 1000W at a distance of 10 cm from the arm. The amount of light of / cm 2 was investigated. Twice a day twice a day from 3 days before irradiation to 3 weeks after irradiation, same pair of the sample containing tangeretine prepared in Example 1-6 and Comparative Example 1-6 and the base without tangeretine Was applied to. Here, in the case of the pack formulations of Example 5 and Comparative Example 5, after the application was removed after 15 minutes. For each of the above, the degree of pigmentation of Examples and Comparative Examples was visually determined, and the results are shown in Table 10 below.
상기 표 10에서 보는 바와 같이 실시예 1-6에 따라 제조된 탄게레틴을 함유한 미백 연고 및 화장료는 피시험자 20 명중에서 최소 10명 이상에 대해 미백 효과를 나타냈고, 특히 많은 양의 탄게레틴이 적용된 실시예 1과 비교예 1의 비교실험에서는 35%가 뚜렷한 색소 침착 저해 효과를 나타내었다. 또한 피부 내에서 어떤 부작용도 나타내지 않아 탄게레틴은 안전하고 기미나 주근깨 개선에 우수한 효과가 있는 피부 미백제임을 알 수 있다.
As shown in Table 10, the whitening ointment and the cosmetic containing tangeretine prepared according to Example 1-6 showed a whitening effect on at least 10 or more among 20 subjects, and particularly a large amount of tangeretine In the comparative experiments of Example 1 and Comparative Example 1 applied, 35% showed a marked inhibitory effect on pigmentation. In addition, it does not show any side effects in the skin, it can be seen that tangeretin is a skin lightening agent that is safe and has an excellent effect on improving freckle and freckles.
[실험예 4] 탄게레틴의 임상에서의 주름개선 효과 시험Experimental Example 4 Anti-wrinkle Effect Test of Tangeretetin in Clinical
주름 개선 효과의 평가는 다음과 같이 실시하였다. 20명의 30~40세 여성을 무작위로 2개군으로 나누어 실시예 2와 비교예 2의 크림을 매일 아침 저녁 2회씩 세안 후 크림 적당량을 눈가를 중심으로 2개월간 연속적으로 바르게 하였다. 각 피검자의 주름 개선 효과를 육안 관찰을 통하여 평가하였다. 실험 결과는 하기의 표 11에 나타낸 바와 같다. Evaluation of the wrinkle improvement effect was performed as follows. Twenty 30-40 year old women were randomly divided into two groups, and the creams of Example 2 and Comparative Example 2 were washed two times each morning and evening, and then an appropriate amount of cream was applied continuously for two months centering on the eyes. Wrinkle improvement effect of each subject was evaluated through visual observation. The experimental results are shown in Table 11 below.
상기 표 10에서 보는 바와 같이 실시예 2에 따라 제조된 탄게레틴을 함유한 크림은 피시험자 20 명중에서 16명에 대해 주름개선 효과를 나타내었으며, 또한 피부 내에서 어떤 부작용도 나타내지 않아 탄게레틴은 안전하고 우수한 효과가 있는 피부 주름개선제임을 알 수 있다. As shown in Table 10, the cream containing the tangeretine prepared according to Example 2 exhibited an anti-wrinkle effect on 16 out of 20 subjects, and also did not show any side effects in the skin. And it can be seen that it is an excellent skin wrinkle improver.
Claims (6)
탄게레틴(tangeretin)을 조성물 총량에 대하여 0.00001 내지 10.0 중량%를 포함하는 것을 특징으로 하는 조성물.The method according to any one of claims 1 to 3,
Tangerintin (tangeretin) comprises 0.00001 to 10.0% by weight based on the total amount of the composition.
상기 조성물은 화장료 조성물인 것을 특징으로 하는 조성물.4. The method according to any one of claims 1 to 3,
The composition is a composition, characterized in that the cosmetic composition.
상기 조성물은 약제학적 조성물인 것을 특징으로 하는 조성물.4. The method according to any one of claims 1 to 3,
Wherein said composition is a pharmaceutical composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120011003A KR20130089559A (en) | 2012-02-02 | 2012-02-02 | Anti-aging composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120011003A KR20130089559A (en) | 2012-02-02 | 2012-02-02 | Anti-aging composition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130089559A true KR20130089559A (en) | 2013-08-12 |
Family
ID=49215438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120011003A KR20130089559A (en) | 2012-02-02 | 2012-02-02 | Anti-aging composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130089559A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101651833B1 (en) * | 2015-07-17 | 2016-09-19 | 명지대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising extract of citrus preicarp |
JPWO2018207952A1 (en) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | Hair growth and / or hair growth composition |
-
2012
- 2012-02-02 KR KR1020120011003A patent/KR20130089559A/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101651833B1 (en) * | 2015-07-17 | 2016-09-19 | 명지대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising extract of citrus preicarp |
JPWO2018207952A1 (en) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | Hair growth and / or hair growth composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20130088912A (en) | Skin external composition containing tangeretin and egcg | |
KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR20140033815A (en) | Derivatives of quinic acid and the use thereof | |
KR101508694B1 (en) | Cosmetic Composition for the Skin Whitening Comprising the Lapachol | |
KR20190137328A (en) | Skin external application composition for anti-aging containing Rhodotypos scandens extract | |
KR100860604B1 (en) | Cosmetic composition comprising extract of pinus strobus bark | |
KR20130005616A (en) | Skin whitening agent | |
KR101462692B1 (en) | Skin whitening cosmetics | |
KR20130089559A (en) | Anti-aging composition | |
KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
KR101786606B1 (en) | cosmetics containing tetrandrine | |
KR102048713B1 (en) | cosmetics containing boswellic acid | |
KR101460900B1 (en) | Cosmetic composition for skin whitening, regeneration or moisturizing comprising epifriedelanol | |
KR101460901B1 (en) | Cosmetic composition for skin whitening, regeneration or moisturizing comprising amarogentin | |
KR20150057737A (en) | Whitening cosmetics composition | |
KR102160306B1 (en) | skin whitening agent | |
KR100467501B1 (en) | A cosmetic composite | |
KR100678865B1 (en) | Cosmetic composition for skin whitening comprising ramulus mori extract and carnitine as active ingredient | |
KR20140071716A (en) | Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent | |
KR102272476B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising isopimpinellin | |
KR102348148B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dihydroartemisinin | |
KR20140090527A (en) | A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis | |
KR20070079390A (en) | Cosmetic composition for skin whitening | |
KR20040083843A (en) | Cosmetic Compositions for Skin-Whitening Comprising Phytolight and Lactate as Active Ingredients | |
KR102700608B1 (en) | Composition for skin improvement containing rehmapicroside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |